T247 is a potent and selective HDAC3 inhibitor with IC50 of 0.24 uM, >75-fold selectivity over HDAC1 and no activity against HDAC4/6/8.
T247 induces dose-dependent selective increase of NF-κB acetylation in human colon cancer HCT116 cells, induces growth inhibition of cancer cells, and activates HIV gene expression in latent HIV-infected cells.
T247 shows promising activity for anticancer and antiviral benefits.
T247 also decreases TMEM16A expression and functional activity in both prostatic cancer cell line PC-3 and the breast cancer cell line YMB-1.
